MedTrace Logo

Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis

NCT01313221 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2017-03-15

Study results available
· View outcomes & findings →

Summary

To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with moderate to severe plaque psoriasis.

Conditions

Interventions

BIOLOGICAL

etanercept

Administered by subcutaneous injection

DRUG

Topical agents

Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following: * hydrocortisone 2.5% * betamethasone valerate 0.1% * betamethasone dipropionate 0.05% * clobetasol 0.05% * calcitriol * calcipotriol plus betamethsone dipropionate 0.05%

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-12-31
Completion
2013-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313221 on ClinicalTrials.gov